company background image
INKT logo

MiNK Therapeutics NasdaqCM:INKT Stock Report

Last Price

US$0.91

Market Cap

US$31.6m

7D

2.1%

1Y

-52.4%

Updated

28 Mar, 2024

Data

Company Financials +

MiNK Therapeutics, Inc.

NasdaqCM:INKT Stock Report

Market Cap: US$31.6m

INKT Stock Overview

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.

INKT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

MiNK Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MiNK Therapeutics
Historical stock prices
Current Share PriceUS$0.91
52 Week HighUS$3.34
52 Week LowUS$0.75
Beta0.11
1 Month Change-3.29%
3 Month Change-15.11%
1 Year Change-52.45%
3 Year Changen/a
5 Year Changen/a
Change since IPO-92.43%

Recent News & Updates

Recent updates

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

Oct 26
MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Jun 28
Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?

Mar 18
Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?

MiNK Therapeutics GAAP EPS of -$0.18

Aug 16

MiNK Therapeutics GAAP EPS of -$0.18

Aug 09

MiNK Therapeutics A Bargain For Potential Cell Therapies

Jun 23

We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely

May 05
We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely

Shareholder Returns

INKTUS BiotechsUS Market
7D2.1%0.9%0.4%
1Y-52.4%10.3%28.8%

Return vs Industry: INKT underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: INKT underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is INKT's price volatile compared to industry and market?
INKT volatility
INKT Average Weekly Movement8.6%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: INKT has not had significant price volatility in the past 3 months.

Volatility Over Time: INKT's weekly volatility has decreased from 15% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201731Jen Buellhttps://minktherapeutics.com

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

MiNK Therapeutics, Inc. Fundamentals Summary

How do MiNK Therapeutics's earnings and revenue compare to its market cap?
INKT fundamental statistics
Market capUS$31.58m
Earnings (TTM)-US$22.46m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INKT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$22.46m
Earnings-US$22.46m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.65
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did INKT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.